Literature DB >> 11286729

Dendritic cells resurrect antigens from dead cells.

M Larsson1, J F Fonteneau, N Bhardwaj.   

Abstract

Antigens that do not normally access the cytoplasm of antigen-presenting cells, such as certain tumor and viral antigens, become targets of cytotoxic T lymphocytes (CTLs). Over the past 25 years, substantial evidence has emerged for an 'exogenous' pathway for loading MHC class I molecules. Dendritic cells are potent stimulators of T-cell responses and can induce CD8(+) CTLs by phagocytosis of dead tumor or virus-infected cells. Here, Marie Larsson and colleagues discuss the role of dendritic cells in stimulating MHC class I-restricted T-cell responses by exogenous routes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11286729     DOI: 10.1016/s1471-4906(01)01860-9

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  34 in total

1.  Vaccines to die for.

Authors:  N P Restifo
Journal:  Nat Biotechnol       Date:  2001-06       Impact factor: 54.908

2.  The apoptotic-cell receptor CR3, but not alphavbeta5, is a regulator of human dendritic-cell immunostimulatory function.

Authors:  Mojca Skoberne; Selin Somersan; Wanda Almodovar; Tuan Truong; Kseniya Petrova; Peter M Henson; Nina Bhardwaj
Journal:  Blood       Date:  2006-04-13       Impact factor: 22.113

3.  Irradiation enhances dendritic cell potential antitumor activity by inducing tumor cell expressing TNF-α.

Authors:  Lijia Chang; Zhengzheng Zhang; Fang Chen; Wen Zhang; Shuang Song; Shuxia Song
Journal:  Med Oncol       Date:  2017-02-13       Impact factor: 3.064

4.  Presentation of human T cell leukemia virus type 1 (HTLV-1) Tax protein by dendritic cells: the underlying mechanism of HTLV-1-associated neuroinflammatory disease.

Authors:  Sharrón L Manuel; Todd D Schell; Edward Acheampong; Saifur Rahman; Zafar K Khan; Pooja Jain
Journal:  J Leukoc Biol       Date:  2009-08-05       Impact factor: 4.962

5.  Presentation of tumor antigens by dendritic cells genetically modified with viral and nonviral vectors.

Authors:  Michal Lotem; Yangbing Zhao; John Riley; Patrick Hwu; Richard A Morgan; Steven A Rosenberg; Maria R Parkhurst
Journal:  J Immunother       Date:  2006 Nov-Dec       Impact factor: 4.456

Review 6.  Whole tumor antigen vaccines.

Authors:  Cheryl Lai-Lai Chiang; Fabian Benencia; George Coukos
Journal:  Semin Immunol       Date:  2010-03-30       Impact factor: 11.130

7.  Cross-presentation of human cytomegalovirus pp65 (UL83) to CD8+ T cells is regulated by virus-induced, soluble-mediator-dependent maturation of dendritic cells.

Authors:  Géraldine Arrode; Claire Boccaccio; Jean-Pierre Abastado; Christian Davrinche
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

Review 8.  Concepts of immunotherapy for glioma.

Authors:  Mira A Patel; Drew M Pardoll
Journal:  J Neurooncol       Date:  2015-06-13       Impact factor: 4.130

9.  Linear and branched glyco-lipopeptide vaccines follow distinct cross-presentation pathways and generate different magnitudes of antitumor immunity.

Authors:  Olivier Renaudet; Gargi Dasgupta; Ilham Bettahi; Alda Shi; Anthony B Nesburn; Pascal Dumy; Lbachir BenMohamed
Journal:  PLoS One       Date:  2010-06-21       Impact factor: 3.240

10.  Antigen transport and cytoskeletal characteristics of a distinct enterocyte population in inflammatory bowel diseases.

Authors:  Sabine Kersting; Matthias Bruewer; Guido Schuermann; Axel Klotz; Markus Utech; Matthias Hansmerten; Christian F Krieglstein; Norbert Senninger; Joerg-Dieter Schulzke; Hassan Y Naim; Klaus-Peter Zimmer
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.